Finland· FI-REL-REL19149
Zevalin
A ibritumomab tiuxetan 90y product containing ibritumomab tiuxetan, registered in Finland by Ceft Biopharma s.r.o.. The same ATC class is registered in 7 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Ibritumomab tiuxetan 90y is registered in 7 of 19 countries.
Countries holding a registration under ATC V10XX02 (ibritumomab tiuxetan 90y), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 5 of them publish a price we can compare per daily dose
Ibritumomab tiuxetan 90y · ATC V10XX02
7 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Ireland
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Ibritumomab tiuxetan
- Manufacturer
- Ceft Biopharma s.r.o.
- Country
- Finland (FI)
- ATC code
- V10XX02
- ATC class
- Ibritumomab tiuxetan 90Y
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
199 interactions on record for ibritumomab tiuxetan 90y.
Graded by severity as the source publishes them — 127 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ibritumomab tiuxetan 90y · interactions on record
199 records
- 127 severe
- 72 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ibritumomab tiuxetan 90y in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- Japanイブリツモマブ チウキセタン（遺伝子組換え）・塩化イットリウム（９０Ｙ）ムンディファーマ
- BelgiumZevalin 1.6 mg/mlCeft Biopharma
- SpainZEVALIN 1,6 mg/ml, EQUIPO REACTIVO PARA LA PREPARACION DE UN RADIOFARMACO PARA PERFUSIONCeft Biopharma S.R.O.
- United KingdomZevalin 3.2mg/2ml kit for radiopharmaceutical preparationCurium Pharma UK Ltd
- IrelandZevalinCeft Biopharma s.r.o
- PolandZevalinCeft Biopharma s.r.o.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b3d8398c-ea90-4cab-96d8-c9ab9f029d02 GET /v1/drugs/b3d8398c-ea90-4cab-96d8-c9ab9f029d02?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "valmisteyhdistelmä radioaktiivista infuusionestettä varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "1.6 mg/ml",
"atc_label": "ibritumomabitiuksetaani (90Y)",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/03/264/001",
"fimea_rel_id": "REL19149",
"authorised_at": "2004-01-16"
}See everything about ibritumomab tiuxetan 90y.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.